| # | Title | Journal | Year | Citations |
|---|
| 1 | Chimeric antigen receptor T-cell therapy — assessment and management of toxicities | Nature Reviews Clinical Oncology | 2018 | 1,659 |
| 2 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) | Clinical Infectious Diseases | 2021 | 292 |
| 3 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), andPseudomonas aeruginosawith Difficult-to-Treat Resistance (DTR-P. aeruginosa) | Clinical Infectious Diseases | 2021 | 251 |
| 4 | 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial | Lancet Haematology,the | 2020 | 201 |
| 5 | Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' | Nature Reviews Clinical Oncology | 2018 | 114 |
| 6 | Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area | American Journal of Health-System Pharmacy | 2002 | 113 |
| 7 | The oncologic burden of hepatitis C virus infection: A clinical perspective | Ca-A Cancer Journal for Clinicians | 2017 | 88 |
| 8 | Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia | Blood Cancer Journal | 2021 | 85 |
| 9 | Tacrolimus‐associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation | American Journal of Hematology | 2013 | 81 |
| 10 | Statin use in primary inflammatory breast cancer: a cohort study | British Journal of Cancer | 2013 | 80 |
| 11 | Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens | Haematologica | 2021 | 80 |
| 12 | Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent | Pharmacotherapy | 2015 | 77 |
| 13 | Outcomes of children exposed in uteroto chemotherapy for breast cancer | Breast Cancer Research | 2014 | 75 |
| 14 | Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole | Clinical Infectious Diseases | 2018 | 73 |
| 15 | Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients | Clinical Infectious Diseases | 2019 | 71 |
| 16 | Stress Ulcer Prophylaxis | Critical Care Medicine | 2016 | 70 |
| 17 | Comparison of Resting Energy Expenditure Prediction Methods With Measured Resting Energy Expenditure in Obese, Hospitalized Adults | Journal of Parenteral and Enteral Nutrition | 2009 | 69 |
| 18 | Improving Adherence to Oral Cancer Therapy in Clinical Practice | Pharmacotherapy | 2014 | 67 |
| 19 | Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies | Bone Marrow Transplantation | 2000 | 66 |
| 20 | An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines | Gynecologic Oncology | 2005 | 65 |
| 21 | Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients | Bone Marrow Transplantation | 2017 | 65 |
| 22 | Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient | Antimicrobial Agents and Chemotherapy | 2016 | 61 |
| 23 | Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality | American Journal of Hematology | 2021 | 59 |
| 24 | Treating Leukemia in the Time of COVID-19 | Acta Haematologica | 2021 | 57 |
| 25 | Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum β-Lactams for Major Gram-Negative Bacterial Pathogens | Clinical Infectious Diseases | 2017 | 56 |
| 26 | Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer | JAMA Oncology | 2018 | 56 |
| 27 | Aerosolized ribavirin: the most expensive drug for pneumonia | Transplant Infectious Disease | 2016 | 52 |
| 28 | Chimeric Antigen Receptor T Cells in Hematologic Malignancies | Pharmacotherapy | 2017 | 52 |
| 29 | Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999–2015 | Clinical Infectious Diseases | 2017 | 50 |
| 30 | Cyclin‐Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future | Pharmacotherapy | 2016 | 48 |
| 31 | Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study | Clinical Infectious Diseases | 2021 | 48 |
| 32 | A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS) | Blood | 2018 | 48 |
| 33 | Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer | Journal of Oncology Pharmacy Practice | 2015 | 45 |
| 34 | Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice | JACCP Journal of the American College of Clinical Pharmacy | 2019 | 45 |
| 35 | American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation | Transplantation and Cellular Therapy | 2021 | 45 |
| 36 | STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition | Clinical Cancer Research | 2021 | 44 |
| 37 | Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation | Biology of Blood and Marrow Transplantation | 2018 | 43 |
| 38 | Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era | Clinical Infectious Diseases | 2021 | 43 |
| 39 | Decrease post-transplant relapse using donor-derived expanded NK-cells | Leukemia | 2022 | 43 |
| 40 | Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint | Clinical Infectious Diseases | 2019 | 42 |
| 41 | Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice | Transplant Infectious Disease | 2014 | 41 |
| 42 | Eculizumab for transplant‐associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients | European Journal of Haematology | 2018 | 41 |
| 43 | Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock* | Critical Care Medicine | 2020 | 41 |
| 44 | Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation | Biology of Blood and Marrow Transplantation | 2018 | 39 |
| 45 | Activity of Cefiderocol and Comparators against Isolates from Cancer Patients | Antimicrobial Agents and Chemotherapy | 2020 | 38 |
| 46 | Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience | Antiviral Research | 2016 | 37 |
| 47 | Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib | Cancer Chemotherapy and Pharmacology | 2016 | 36 |
| 48 | BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD | Blood | 2014 | 35 |
| 49 | Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia | Cancer | 2021 | 34 |
| 50 | Analgesic and Antiemetic Requirements After Minimally Invasive Surgery for Early Cervical Cancer: A Comparison Between Laparoscopy and Robotic Surgery | Annals of Surgical Oncology | 2013 | 33 |
